Compliance Expectations for Significant Data Fiduciaries in Healthcare Under DPDP
The DPDP Act sets stricter expectations for organisations that process personal data at scale or in sensitive contexts. Healthcare and pharma fall squarely into both categories.
This article explains what compliance looks like for significant data fiduciaries in healthcare, why the bar is higher, and how pharma companies must adapt their operations to meet it.
What Is a Significant Data Fiduciary Under DPDP?
A significant data fiduciary is an organisation that processes large volumes of personal data or sensitive data with potential risk to individuals.
• Handles large-scale personal data
• Processes sensitive healthcare data
• Operates in high-impact sectors like pharma
• Faces higher compliance obligations
Why Healthcare Faces Higher Compliance Expectations?
Healthcare data is deeply personal and carries the potential for real harm if misused. Even when data is used for professional engagement or education, it can reveal patterns about individuals, behaviour, and health related decisions.
This also relates to identifying the correct data principal. Learn more in data principal under DPDP.
The DPDP Act recognises this heightened risk. As a result, healthcare organisations that process large volumes of personal data or sensitive data face stronger expectations around governance, transparency, and control.
For pharma companies, this means that compliance must extend beyond legal documentation and into daily operational practice.
What Makes a Healthcare Organisation a Significant Data Fiduciary?
Significant data fiduciary classification is based on several factors rather than a single threshold.
The DPDP significant data fiduciary meaning is defined by scale, sensitivity, and potential risk of harm.
These include the volume of personal data processed, the sensitivity of that data, the likelihood of harm if data is misused, and the broader impact on public interest.
Healthcare and pharma organisations often meet multiple criteria simultaneously. They process large datasets, handle sensitive information, and operate in a sector where trust is essential.
Governance Expectations Under DPDP
One of the most important compliance expectations for significant data fiduciaries is governance maturity.
This reflects the need for strong healthcare data governance under DPDP across all organisational layers.
Healthcare organisations must demonstrate that data protection is actively managed at an organisational level. This includes defined roles and responsibilities, clear escalation paths, and ongoing oversight.
Compliance cannot be delegated entirely to vendors or treated as a periodic exercise. It must be embedded into organisational structure and decision making.
Consent Management as a Core Compliance Requirement
Consent management becomes a central pillar of compliance for significant data fiduciaries.
This is where a consent management platform for pharma becomes essential to enforce consent across systems.
Consent must be explicit, purpose-specific, and enforceable. Healthcare organisations must be able to show when consent was obtained, for what purpose, and how it is enforced across systems.
This affects how doctor engagement, patient programs, and marketing campaigns are designed. Consent must be checked at the point of execution, not just recorded at the point of collection.
This is where DPDP-compliant HCP marketing architectures become essential for pharma companies operating under higher scrutiny.
System and Technology Readiness Expectations
Technology systems used by significant data fiduciaries must support compliance by design.
CRMs, marketing platforms, analytics tools, and AI systems must be capable of tracking consent, enforcing purpose limitation, and generating audit trails.
This limitation is discussed in why pharma CRMs fail at consent tracking.
Systems that allow data use without validation expose organisations to compliance risk. Under DPDP, regulators are likely to examine whether systems are fit for purpose, not just whether policies exist.
Without a structured pharma data governance solution, system-level compliance becomes difficult to sustain.
Audit Readiness and Documentation
Significant data fiduciaries must be prepared for audits.
This includes maintaining clear documentation of data flows, consent mechanisms, vendor relationships, and processing purposes. Audit readiness is not about creating documents on demand. It is about having systems and processes that can demonstrate compliance naturally.
Healthcare organisations that rely on manual or fragmented documentation often struggle under scrutiny.
Vendor and Processor Oversight
Healthcare organisations frequently work with agencies, technology vendors, and service providers.
Read more in third-party vendor responsibility under DPDP
As significant data fiduciaries, they must ensure that these partners process data strictly under documented instructions. Access controls, contractual safeguards, and monitoring mechanisms become critical.
Responsibility does not shift to vendors simply because they handle execution. Oversight remains with the healthcare organisation.
Data Minimisation and Retention Controls
Another compliance expectation for significant data fiduciaries is disciplined data minimisation.
Healthcare organisations must collect only the data necessary for a defined purpose and retain it only for as long as needed. Legacy data stored without clear purpose increases risk.
Retention policies must be enforced in practice, not just defined on paper.
Handling Consent Withdrawal and Data Rights
Significant data fiduciaries must enable individuals to exercise their rights under DPDP.
This includes the ability to withdraw consent and have processing stop promptly. Healthcare organisations must ensure that withdrawal requests propagate across all systems and partners.
Failure to honour withdrawal requests exposes organisations to regulatory action and reputational damage.
AI Governance Under Higher Scrutiny
AI driven healthcare marketing and analytics introduce additional compliance considerations.
Significant data fiduciaries must ensure that AI models are trained on lawfully collected data and that outputs respect consent scope and purpose limitation.
Governance frameworks must account for how AI systems process personal data and how they respond to changes in consent status.
Why Compliance Is an Ongoing Obligation?
Compliance expectations for significant data fiduciaries are not static.
As healthcare organisations adopt new technologies, expand digital engagement, and integrate AI, compliance obligations evolve. Continuous monitoring and improvement are required.
Treating compliance as a one time project leaves organisations exposed as operations change.
How Healthcare Organisations Can Meet Significant Data Fiduciary Requirements
• Implement strong governance frameworks
• Adopt consent-first marketing systems
• Ensure audit-ready documentation
• Monitor vendor compliance continuously
• Enable real-time consent enforcement
Closing Perspective and CTA
Compliance expectations for significant data fiduciaries reflect a simple reality: healthcare data carries heightened responsibility, and the law treats it that way.
Meeting that bar takes more than policies. It requires systems, workflows, and governance built for accountability — not retrofitted to it.
If your organisation operates as a significant data fiduciary, your compliance requirements sit well above the standard DPDP baseline. See how a DPDP-compliant HCP marketing platform enables governance, consent enforcement, and audit-ready workflows across pharma engagement — built for compliance, designed for scale.
Frequently Asked Questions on Compliance for Significant Data Fiduciaries
They include enhanced governance, consent enforcement, audit readiness, and system level controls.
Because they process large volumes of sensitive personal data with high potential impact.
Yes. Marketing workflows face higher scrutiny and must be consent first and auditable.
Yes. Systems must support consent tracking and enforcement.
No. Responsibility remains with the healthcare organisation.
Yes. AI systems must comply with DPDP and governance expectations.
Consequences may include penalties, audits, and operational disruption.
Ready to Deploy AI in Your Pharma Operations?
Talk to our team about your HCP data, consent, or engagement challenges. No pitch — just a real conversation about what you need.
